Michael Campos, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Michael Campos, MD sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed early-phase tilt upper half by trial count

Michael Campos, MD: 1 sponsored US clinical trial, none currently recruiting.

Michael Campos, MD sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alpha-1 Antitrypsin Deficiency, with 1 trials.

Mid-pack sponsor footprint

Michael Campos, MD is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

How the Michael Campos, MD early-phase archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Alpha-1 Antitrypsin Deficiency (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Michael Campos, MD: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Michael Campos, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Michael Campos, MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Michael Campos, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Michael Campos, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Michael Campos, MD page

1 registered trials is a research-attention snapshot, not an endorsement of Michael Campos, MD or any single study.

  • None of Michael Campos, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Alpha-1 Antitrypsin Deficiency is the condition Michael Campos, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alpha-1 Antitrypsin Deficiency trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Michael Campos, MD pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.